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Important pathophysiological changes occur in chol-
angiocytes in response to injury. These will be addressed in
the review, with particular emphasis on neuroendocrine
factors and morphogenic signaling pathways activated in
reactive cholangiocytes.
Cholangiocytes are the epithelial cells that line the bile
ducts. Along the biliary tree, two different kinds of chol-
angiocytes exist: small and large cholangiocytes. Each type
has important differences in their biological role in physi-
ologic and pathologic conditions. In response to injury,
cholangiocytes become reactive and acquire a
neuroendocrine-like phenotype with the secretion of a
number of peptides. These molecules act in an autocrine/
paracrine fashion to modulate cholangiocyte biology and
determine the evolution of biliary damage. The failure of
suchmechanisms is believed to inﬂuence the progression of
cholangiopathies, a group of diseases that selectively target
biliary cells. Therefore, the understanding of mechanisms
regulating cholangiocyte response to injury is expected to
foster the development of new therapeutic options to treat
biliary diseases. In this review, we discuss the most recent
ﬁndings in the mechanisms driving cholangiocyte adapta-
tion to damage, with particular emphasis on molecular
pathways that are susceptible of therapeutic intervention.
Morphogenic pathways (Hippo, Notch, Hedgehog), which
have been recently shown to regulate biliary ontogenesis
and response to injury, are also reviewed as well as the re-
sults of ongoing clinical trials evaluating new drugs
for the treatment of cholangiopathies. (Cell Mol Gastro-
enterol Hepatol 2015;1:368–380; http://dx.doi.org/10.1016/
j.jcmgh.2015.05.005)
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http://dx.doi.org/10.1016/j.jcmgh.2015.05.005Twith critical metabolic functions that involve diges-
tion of food and clearance of toxic substances. At the level of
the bile canaliculus, hepatocytes secrete bile, which is then
carried to the duodenum through a complex network of bile
ducts lined by cholangiocytes.1–3Under physiologic conditions, cholangiocytes actively
contribute to the ﬁnal composition and volume of bile
secretion by basal and hormone-regulated events.4 In normal
conditions, one of the most important and well-studied
functions of cholangiocytes is secretin-induced release of
bicarbonate into bile. The binding of secretin to the secretin
receptor (SR) on the basolateral membrane of cholangiocytes
leads to the formation of adenosine 30,50-cyclic mono-
phosphate (cAMP), protein kinase A (PKA)-dependent
phosphorylation of cystic ﬁbrosis transmembrane conduc-
tance regulator (CFTR), and the subsequent extrusion of Cl
in the lumen of bile ducts. Driven by the Cl gradient across
the plasmamembrane, the activation of the apical Cl/HCO3

anion exchanger 2 (AE2) culminates in the net excretion of
bicarbonate in bile,5 with passive inﬂux of water (Figure 1).
As a result, cholangiocytes participate to up to 40% of the so-
called bile salt–independent bile ﬂow.6
Cholangiocytes are the speciﬁc target of a heterogeneous
group of human diseases, termed cholangiopathies, that
have deep consequences on the biology of these cells.7 In
the present review, we discuss the differences in the
structure and function of cholangiocytes and underline the
main ﬁndings in biliary pathophysiology of the last 10 years.
The clinical implications of ongoing research are also spe-
ciﬁcally addressed.
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Function of Cholangiocytes
The biliary epithelium is composed of intrahepatic and
extrahepatic bile ducts lined by cholangiocytes.8 The human
intrahepatic biliary epithelium is classiﬁed by size: hepatic
ducts (>800 mm), segmental ducts (400–800 mm), area ducts
(300–400 mm), septal bile ducts (100 mm), interlobular ducts
(15–100 mm), and bile ductules (<15 mm).9–11 The intra-
hepatic biliary epithelium of rodents is formed by ducts of
different sizes, small (<15 mm in diameter) and large (>15
mm).12,13 The cholangiocytes lining small and large bile ducts
have been morphologically and functionally categorized into
small and large cholangiocytes, respectively.12–15 With
regards to cellular structure, the small cholangiocytes are
cuboidal, but the larger cholangiocytes in larger bile ducts are
more columnar in shape.9–11 Moreover, small cholangiocytes
are poorly specialized and have a high nucleus/cytoplasm
ratio whereas large cholangiocytes are supplied with plenty
of organelles and a small nucleus/cytoplasm ratio.16 The
large, but not the small, cholangiocytes have cilia, which act as
chemo- and mechanosensors within the bile duct lumen.17
The expression of molecules involved in secretin-
stimulated biliary secretion also differs along the biliary
epithelium. SR, CFTR, and anion exchanger 2 (AE2) are only
expressed by large cholangiocytes and are responsible for
the majority of biliary ﬂuid secretion through the activation
of a cAMP-dependent pathway.12,13 In small cholangiocytes,
on the other hand, Ca2þ-activated signaling pathways seem
predominant. Indeed, the activation of purinergic receptors
in small and large cholangiocytes induces Ca2þ-dependent
Cl secretion via transmembrane member 16A (TMEM16A),
providing an alternative route to the secretin-stimulated
cAMP-dependent ductal ﬂuid secretion.18,19
Functionally, large cAMP-dependent cholangiocytes are
more susceptible to damage whereas small cholangiocytes
are more resistant to liver injury.12,20–22 During damage of
large cholangiocytes, small cholangiocytes replenish the
biliary epithelium. Again, the ampliﬁcation of Ca2þ-depen-
dent signaling pathways in small cholangiocytes is essential
in driving the de novo acquisition of large cholangiocyte
phenotypes (see Figure 1).20,21Figure 1. (See previous page). Overview of cholangiocyte ro
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they respond to injury or stress by enhanced prolifera-
tion.3,23,24 Compensatory responses to liver injury include
biliary hyperplasia, ductular reaction, and ductopenia.
Biliary hyperplasia (characterized by proliferation/loss of
cholangiocytes as observed in cholestatic liver diseases such
as primary sclerosing cholangitis) is associated with
enhanced biliary secretion of HCO3
 in bile, which may be a
compensatory protective mechanism for the injured biliary
epithelium.25 Ductopenia is evidenced by the damage of bile
ducts in response to toxins or in certain diseases such as
biliary atresia.15,20,21,26,27 The hepatic artery is the main
blood supplier of the biliary epithelium within the peri-
biliary vascular plexus (PBP). The PBP secretes a number of
angiogenic factors such as vascular endothelial growth fac-
tor (VEGF) that have been shown to regulate biliary prolif-
eration in experimental models of cholestasis.28–31Changes of the Biliary Epithelium in
Pathologic Conditions
Pathophysiology of Biliary Response to Injury
Cholestatic liver diseases represent a heterogeneous
group of diseases characterized by an impairment of bile
formation or bile ﬂow that can arise at the hepatocellular or
cholangiocellular level.32 Emblematic diseases in this group
are primary biliary cirrhosis (PBC) and primary sclerosing
cholangitis (PSC).33 The current various animal models allow
a better insight into the signaling pathways involved in the
development of cholestasis. Such studies may provide po-
tential treatment strategies to restore impaired secretory
functions of hepatocytes and cholangiocytes, or to modulate
the response of these cells to liver injury. Speciﬁc types of liver
injury activate the proliferation of particular cholangiocyte
subpopulations (ie, large/small).15,20,21 In most instances,
biliary proliferation contributes to the major part of the
ductular reaction. However, new ductules may also originate
from activated progenitor cells or from cells that have entered
from the circulation and differentiate into liver cells.23,34,35
Cholangiocyte response to injury is an articulated event,
which retains a “double face” in pathophysiologic terms.le in biliary functions. (A) Intrahepatic bile ducts are lined by
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Table 1.Summarizing the Main Neuroendocrine Factors
Involved in Cholangiocyte Response to Injury
Molecule Functions Reference
Secretin Stimulates the proliferation of both
normal and BDL large cholangiocytes
38
Produced by cholangiocytes and S cells,
induces the up-regulation of VEGF
and NGF via down-regulation of
microRNA 125b and let7a
37, 39
VEGF As a component of PDX-1-induced
neuroendocrine-like
transdifferentiation of cholangiocytes,
stimulates biliary proliferation via an
autocrine mechanism
29, 43
Sustains cholangiocyte proliferation and
PBP reactive expansion after BDL
28
Stimulates biliary cystogenesis in
cholangiocytes of the polycystic
kidney rat model
40
Participates to arterial vasculogenesis
during human liver embryogenesis
44
FSH Stimulates cholangiocyte proliferation 45
Histamine Stimulates small cholangiocyte




proliferation via the activation of the
histamine receptor H2
47
Reduces cholangiocyte proliferation via
the activation of the histamine
receptor H3
57
Increases the growth of
cholangiocarcinoma cells and the
synthesis of VEGF
59
Estrogens Stimulate cholangiocyte proliferation and
prevent apoptosis in BDL rats
49, 50
NGF Stimulates cholangiocyte proliferation
(additive effect in combination with
estrogens)
48
Serotonin Inhibits cholangiocyte proliferation and
secretory activities
52, 53
Melatonin Produced by both pineal gland and
cholangiocytes, inhibits biliary
proliferation and secretory functions
of BDL rats
24, 54, 55
Down-regulates VEGF synthesis by
cholangiocytes
56
BDL, bile duct ligation; FSH, follicle-stimulating hormone;
NGF, nerve growth factor; PBP, peribiliary plexus; PDX-1,
pancreatic and duodenal homeobox 1; VEGF, vascular
endothelial growth factor.
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start to proliferate. This modiﬁcation is functional to
compensate for the anatomic loss of biliary cells and also to
sustain their secretory activities.36 In most instances, how-
ever, biliary proliferation eventually subsides, and apoptotic
mechanisms become prevalent with the development of
ductopenia.7 Along with proliferation, cholangiocyte
response to injury is characterized by the so-called neuro-
endocrine-like transdifferentiation, which plays an essential
role not only in sustaining biliary proliferation itself but also
in immune responses, hepatic inﬂammation, and develop-
ment of liver ﬁbrosis.4,23 To this extent, a number of
neuroendocrine factors are synthesized de novo by reactive
cholangiocyte and have been shown to modulate biliary
damage by autocrine/paracrine mechanisms (Table 1).23
In an elegant morphologic study, Gaudio et al31 provided
strong evidence for the autocrine/paracrine role of VEGF in
the regulation of biliary damage. After cholestasis induced
by bile duct ligation (BDL), the PBP undergoes extensive
proliferation to support the increased nutritional and
functional needs of the proliferating biliary epithelium.
However, the proliferation of the PBP only occurs after
cholangiocytes support the autocrine role of the biliary
system by secreting angiogenic factors in the regulation of
biliary function.31 To demonstrate the important role of
angiogenic factors in sustaining biliary growth, we have
shown that secretin stimulates biliary proliferation by
microRNA 125b and let7a-dependent up-regulation of
VEGF-A and nerve growth factor (NGF), respectively.37
Knockout of the SR (which is only expressed by large
cholangiocytes) decreases biliary hyperplasia in cholestatic
mice by down-regulation of cAMP signaling.38
Other studies have demonstrated the proproliferative
effect of VEGF-A and VEGF-C, which increase biliary growth
of normal rats by interaction with VEGF receptors 2 and 3,
respectively. The same study also showed that the in vivo
administration of neutralizing antibodies for VEGF-A/C
decreased BDL-induced biliary hyperplasia.29 The para-
crine effect of VEGFs on biliary functions was also demon-
strated in experiments where the ligation of the hepatic
artery resulted in disappearance of the PBP (the source of
angiogenic factors such as VEGFs), signiﬁcant reduction of
biliary growth (accompanied by enhanced apoptosis), and
reduced secretion of VEGF and bicarbonate by chol-
angiocytes.28 Another study has shown that inhibition of
VEGF expression in cholangiocytes by overexpression of
microRNA-125b (miR-125b) and knockdown of histidine
decarboxylase (the enzyme that regulates histamine syn-
thesis) decreased BDL-induced biliary hyperplasia.39
Consistent with the role of VEGF on biliary functions,
Ren et al40 have shown that VEGF plays an important role in
the infection-induced increase of biliary cystogenesis in
cholangiocytes of the polycystic kidney rat model. Prolonged
feeding of taurocholic acid to BDL rats prevents biliary
damage induced by hepatic artery ligation or caffeic acid by
overexpression of VEGF-A.41,42 Also, cholangiocyte
neuroendocrine-like transdifferentiation, driven by the de
novo expression of pancreatic duodenal homeobox-1, has
been associated with enhanced biliary VEGF expression.43Another study has shown that cholangiocytes generate a
VEGF gradient that is key during arterial vasculogenesis,
whereas angiopoietin-1 signaling from hepatoblasts partic-
ipates in the remodeling of the hepatic artery to sustain
the nutritional demands of the proliferating biliary
epithelium.44
Biliary hyperplasia is also promoted by a number of
growth factors such as NGF, follicle-stimulating hormone
(FSH), gonadotropin-releasing hormone (GnRH), estrogens,
372 Maroni et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 4and the biogenic amine histamine by the interaction with
their speciﬁc receptors.22,45–47 For example, we have shown
that 1) intrahepatic bile ducts secrete NGF and express NGF
receptors, and 2) NGF stimulates (in combination with
estrogens) biliary proliferation by activating the ERK
pathway as well as the phosphatidylinositol 3-kinase
pathway.48 The decrease in intrahepatic bile duct mass
(concomitant with reduced expression of estrogen receptor
a and b and enhanced biliary apoptosis) supports the role of
endogenous estrogens in sustaining the enhanced prolifer-
ative and secretory activities of cholangiocytes during
cholestasis, which may be important during ductopenic
states.49 Also supporting this concept, another study has
shown that estrogens maintain biliary mass and reduce
apoptosis after biliodigestive anastomosis in cholestatic BDL
rats.50 A recent study has also shown that cholangiocytes
express FSH and its receptor and also secrete FSH. In vivo,
FSH increases biliary mass, whereas administration of
antide (a GnRH antagonist blocking FSH secretion) and anti-
FSH antibody to BDL rats decreases cAMP-dependent
cholangiocyte proliferation and biliary mass.
Modulation of biliary FSH expression may be a target for
the management of cholestatic liver diseases.45 FSH as well
as other growth factors including estrogens either directly
or by synergizing NGF, insulin-like growth factor 1, FSH, and
VEGF have been shown to regulate the proliferative and
secretive activities of cystic epithelium of polycystic liver
diseases in rodent models and human cell lines. Also, GnRH
(secreted by the hypothalamus as well as cholangiocytes)
has been shown to stimulate biliary proliferation by both
paracrine/autocrine pathways.51 Disruption of the GnRH/
GnRH-receptor cascade may be an important target for the
management of cholangiopathies.
Conversely, a number of other molecules have been
shown to reduce cholangiocyte proliferation. For example,
the activation of serotonin 1A and 1B receptors inhibits
biliary hyperplasia in cholestatic rats by enhanced IP3/
Ca2þ/protein kinase C signaling and subsequent inhibition
of the cAMP/protein kinase A/Src/extracellular signal-
regulated kinase 1/2 pathway. Cholangiocytes also
secrete serotonin that reduces biliary proliferation during
the course of cholestasis in an autocrine fashion.52 In
addition, they express the neuronal isoform of neuronal
tryptophan hydroxylase, synthesize serotonin, and use se-
rotonin as an autocrine/paracrine signal to regulate biliary
remodeling.53
Other studies have provided evidence for the growth-
limiting function of the hormone melatonin (MT). In chole-
static BDL rats, MT both in vivo and in vitro decreased
biliary hyperplasia by cAMP-dependent down-regulation of
clock gene expression through the interaction with MT1
receptor subtype.24 Furthermore, when BDL rats were
housed in prolonged darkness there was reduced biliary
hyperplasia and ﬁbrosis, which was accompanied by a sig-
niﬁcant increase in the serum levels of MT likely originating
from the pineal gland.54 Hepatic inhibition of arylalkylamine
N-acetyltransferase (the rate-limiting enzyme regulating MT
synthesis) by Vivo-morpholino sequence of arylalkylamine
N-acetyltransferase (which decreases MT hepatic secretion)increases biliary growth and the expression of angiogenic
factors in cholestatic rats.55,56
A number of elegant studies have also been performed to
evaluate the role of histamine on cholangiocyte prolifera-
tion. It has been found in rodent models of cholestasis that
histamine increases or inhibits biliary proliferation by
interacting with either H1-H2 histamine receptors (stimu-
latory) or H3-H4 histamine receptors (inhibitory).22,47,57,58
Stimulation of H3 histamine receptors by H3 histamine re-
ceptor agonist decreases BDL-induced cholangiocyte hy-
perplasia via inhibition of cAMP signaling, thus suggesting a
possible beneﬁcial effect of histamine in cholangiopathies.
Histamine also interacts with the H1 histamine receptor and
increases the proliferation of small cholangiocytes by acti-
vation of IP3/Ca2þ/calmodulin-dependent kinase I/cAMP
response element-binding protein–dependent signaling.58,59
This differential response induced by histamine may be
employed in variable conditions of liver diseases where
either reduction in biliary hyperplasia or regeneration of
liver would be desirable, depending on the injury.
It is evident from these studies that modulation of the
different receptors could be of prime importance while
managing the balance between biliary growth/loss in chol-
angiopathies or posttransplantation. In vivo, GABA induces
the damage of cAMP-dependent large cholangiocytes
concomitant with de novo proliferation of small chol-
angiocytes, which amplify their Ca2þ-dependent signaling
and acquire phenotypes of large cholangiocytes to repair the
damaged biliary epithelium.20,21Emerging Morphogenic Pathways Regulating
Biliary Pathophysiology
Hippo Signaling Pathway. The Hippo signaling pathway
is an evolutionarily conserved pathway that regulates bile
duct differentiation and homeostasis in the liver.60 The core
Hippo signaling pathway is a kinase cascade.61 The apical
membrane-associated four-point-one, ezrin, radixin, moesin
(FERM) domain protein neuroﬁbromin 2 (NF2) directly
binds and recruits the nuclear Dbf2-related family kinase
large tumor suppressor homolog 1/2 (LATS1/2) to the
plasma membrane. Membrane recruitment, in turn, pro-
motes LATS1/2 phosphorylation by the Ste-20 family pro-
tein kinase mammalian STE20-like protein kinase 1/2
(MST1/2), together with the adaptor protein Salvador
homolog 1 (SAV1). In turn, LATS1/2, in a complex with
small regulator protein Mps one binder homolog A (MOB1),
phosphorylates Yes-associated protein (YAP), a transcrip-
tion coactivator. Phosphorylation of YAP deactivates its
transcription coactivator activity through sequestering YAP
in cytoplasm.
YAP is highly expressed in cholangiocytes of both mouse
and human livers, which suggests that YAP plays a role in
cholangiocyte biology.62,63 By use of genetically modiﬁed
mouse models, Zhang et al64 found that transcriptional
regulation activity of YAP was required for bile duct
development. Liver-speciﬁc Yap deletion leads to postnatal
bile duct paucity due to failure formation of primitive ductal
structures around E18.5. Accordingly, increasing YAP
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signiﬁcantly increases the number of primitive ductal
structures and results in bile duct hyperplasia.64 However,
the YAP downstream targets involved in regulating bile duct
development remain to be elucidated.
YAP is also important for determining biliary cell
fate.62,65 Compared with cholangiocytes, hepatocytes main-
tain a lower YAP activity. Increasing hepatocyte YAP activity
through ectopic YAP expression or ablating upstream
negative regulator Mst1/2 dedifferentiates periportal he-
patocytes into ductal cells. Furthermore, Yimlamai et al62
demonstrated that YAP regulates hepatic cell fate determi-
nation directly through Notch signaling, another critical
signaling pathway for bile duct development.
Notch Signaling Pathway. The Notch signaling pathway
contains four transmembrane Notch receptors (Notch-1, -2,
-3, -4) and two types of cell surface ligands, Serrate/Jagged
(Jag-1, -2) or Delta-like (Dll-1, -3, -4).66 The activation of the
Notch signaling requires a cell-cell interaction between the
“transmitting” cell expressing Notch ligands and the
“receiving” cell expressing Notch receptors. Upon ligand
engagement, the Notch receptor is cleaved by the g-secre-
tase complex, leading to the cytoplasmic release of the
Notch intracellular domain (NICD). NICD will then trans-
locate into the nucleus where it binds to the recombination
signal binding protein immunoglobulin Jk (RBP-Jk) to
displace the RBP-Jk-associated corepressors, thereby
allowing the transcription of the Notch target genes. Among
them, the Hairy/Enhancer of split homologs transcription
factors (Hes and Hey), the family of the hepatocyte nuclear
factors (HNF) and the sex-determining region Y-box 9 (Sox-9)
are involved in biliary cell differentiation. Mouse models
deﬁcient in Notch receptor Notch-2,67–69 Notch ligands
Jag-1,70,71 Notch nuclear effector RBP-Jk,72,73 Notch tran-
scription target Hes-1,74 Sox-9, and HNF1b75,76 all show
defects in intrahepatic bile duct tubulogenesis during fetal
development and early postnatal life. Consistently, consti-
tutive activation of the Notch-2 intracellular domain (NICD)
in hepatoblasts during development leads to ectopic for-
mation of tubular and cystic structures, resembling early
malignant biliary lesions.77,78 In agreement with their
physiologic role in the commitment of the biliary lineage,
Notch2, Jagged1, Hes1, Sox-9, and HNF1b are highly
expressed in biliary cells.73,74
Hedgehog Signaling. Both immature and mature chol-
angiocytes produce and respond to the Hedgehog (Hh)
signaling ligands Sonic hedgehog (Shh) and Indian hedgehog
(Ihh).79–81 Shh and Ihh ligands then bind to their trans-
membrane Hedgehog receptor Patched (Ptc), which relieves
the suppression of Smoothened (Smo) and leads to activa-
tion of the Glioblastoma (Gli) family of transcription factors
(Gli1, Gli2, Gli3).79 The important role of the Hedgehog
pathway in cholangiocyte pathogenesis has been demon-
strated with a cholestatic injury model.80,82 Dramatic in-
creases in hepatic expression of Hh ligands and up-
regulation of Hh pathway activity occur after BDL in ro-
dents. Moreover, mice with a genetic ablation of Ptc exhibit
exacerbated ductular and ﬁbrogenic responses. However,the physiologic role and the molecular mechanism of
Hedgehog signaling during maintenance of bile duct ho-
meostasis are not fully understood and remain to be further
investigated.Role of Cholangiocytes in the Development of
Human Chronic Cholestatic Conditions
Primary Sclerosing Cholangitis. Signaling mechanisms
fueling PSC development are being studied in several
different animal models. Among the different rodent models,
MDR2/ mice have been particularly helpful for studying
the development of ﬁbrosis in PSC.83 MDR2/ mice have a
decreased concentration of phosphatidylcholine in bile,
which is known to potentiate the toxicity of bile acids.
Additionally, MDR2/ mice demonstrate leakage of bile
into portal tracts, caused by disrupted tight junctions of the
biliary epithelium, which is responsible for causing inﬂam-
mation and ﬁbrosis.84
Fibrosis is regulated by the expression of several pro/
antiﬁbrotic genes. For example, tissue inhibitor of
metalloproteinase-1 (TIMP-1) mRNA expression is
increased, whereas matrix metalloprotease 13 (MMP-13) is
suppressed in this model. Additionally, a number of proin-
ﬂammatory molecules such as TNFa, interleukin-1b (IL-1b),
IL-6, transforming growth factor-b (TGF-b1), and interferon-
g are overexpressed in MDR2/ mice compared with
controls. Mainly based on experiments on MDR2/ mice,85
new possible treatment options for PSC are currently being
evaluated in clinical trials.
Tabibian et al86 isolated cholangiocytes from livers of
PSC patients, cultured the intrahepatic cholangiocytes, and
further conﬁrmed their purity by immunoﬂuorescence
studies for cholangiocyte speciﬁc markers such as
cytokeratin-19. They showed that PSC cholangiocytes
expressed fewer tight junction proteins (ZO1, indicating
impaired epithelial junctions) and were enlarged in size
with robust ﬁlamentous structures throughout the cell body.
Further, these cholangiocytes exhibited the characteristics
of cellular senescence when compared with normal human
cholangiocytes and H69. Next generation sequencing
conﬁrmed the elevated expression of proinﬂammatory cy-
tokines and chemokines compared with controls. Thus, their
study has provided targets that could potentially be used for
devising treatment protocols for the management of PSC.86
As for many other diseases, genomewide association
studies represent a promising approach not only for dis-
secting the pathophysiology of PSC but also for the identi-
ﬁcation of possible therapeutic targets. To date, a total of 16
genes have been associated with an increased risk of PSC.87
Among others, the single-nucleotide polymorphism located
at chromosomal region 2q35 has attracted the interest of
researchers. This particular single-nucleotide polymorphism
is in close proximity to the G protein-coupled bile acid re-
ceptor (TGR5) gene and has been associated both with PSC
and ulcerative colitis.88 TGR5 is the ﬁrst G-protein coupled
receptor for bile acids that has important roles in energy
expenditure and basal metabolism.89 Interestingly, ﬁve
374 Maroni et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 4mutations in the TGR5 gene have been shown to reduce or
abolish the function of the protein.90 The activation of TGR5
in cholangiocytes is thought to stimulate bicarbonate
secretion,91 possibly contributing to the protection of the
biliary epithelium via the biliary bicarbonate umbrella.25
Primary Biliary Cirrhosis. PBC is an immune-mediated
pathology of the biliary tree characterized by the genera-
tion of antimitochondrial antibodies directed against the
pyruvate dehydrogenase complex (PDC-E2).92 Recent
studies have shown that TLR9 and CD86 expression is
enhanced in B cells of PBC patients.93,94 Proﬁling studies for
cytokines and chemokines have shown that these molecules
are important in the pathogenesis of PBC.95 Further, there is
often involvement of autoreactive CD4þ and CD8þ T cells in
PBC. A number of animal models for PBC have been pro-
posed. Despite the fact that none of them can perfectly
recapitulate the complex interactions of the human disease,
they have proved to be valuable tools to study PBC alter-
ations and explore possible therapeutic targets. Brieﬂy, the
NOD.c3c4 mouse was the ﬁrst animal model to develop PBC-
like characteristics.96 The second mouse model, which is
most frequently used for studying PBC, owing to the simi-
larity of human PBC, is the one expressing the dominant
negative form of TGF-b receptor II (dnTGF-bRII). This
particular mouse model is characterized by higher serum
level of TNFa, interferon-g, and IL-6 when compared with
control animals.97 Similarly, elevated serum cytokines,
lymphocyte inﬁltration around portal tracts, and chol-
angiocyte injury are noted in a third rodent model of PBC,
the IL-2Ra knockout mice model.98
In genetically susceptible individuals, environmental
factors may trigger an immune-mediated injury of chol-
angiocytes. The immunologic events then occur in a step-by-
step manner, starting from antigen presentation, T-cell
differentiation, proliferation, and recruitment, and ﬁnally
resulting in an effector-cell response and production of au-
toantibodies.99 In this context, a number of different signaling
pathways have been implicated in this disease development
or progression, and as such any of these steps could theo-
retically be targeted for treatment of PBC.
Because many pathophysiologic events of the human
disease remain obscure and may differ from the animal
models, caution should be implemented while evaluating
the experimental effects of the manipulation of signaling
pathways. Nonetheless, antibody-mediated therapy, tar-
geted inhibition of cellular pathways relevant to immune
regulation, and cell therapy methods directed toward
reprogramming the immunomodulatory axis remain an
intriguing opportunity to treat PBC patients.100–102
Biliary Atresia. Biliary atresia (BA) is a disease caused by
obstructive cholangiopathy resulting from inﬂammation and
ﬁbrosis of extrahepatic bile ducts. Inﬂammatory reactions
triggered by viral infection have been proposed as the
possible cause of BA by several population studies as well as
studies in murine models.103 Population studies have
proved the presence of human papillomavirus, cytomega-
lovirus, and reovirus in the livers of BA patients.104–106
Evidence from studies in a rhesus-rotavirus infected mu-
rine model of BA as well as from ﬁxed liver tissues from BApatients have shown that there are structural as well as
pathologic changes in the extrahepatic cholangiocytes only.
It was observed that primary cilia were selectively lost from
the extrahepatic and not the intrahepatic cholangiocytes
after rotavirus infection in experimental mice.107,108 Jafri
et al109 found that chemokine expression levels were also
increased in cholangiocytes isolated from rotavirus-infected
mice as well as in virus-infected cholangiocytes in culture. In
their quantitative and qualitative assessments of several
chemokines, they found that macrophage inﬂammatory
protein-2 and monocyte chemotactic protein-1 were up-
regulated after rotavirus infection when compared with
normal in vivo and in vitro conditions.
Cholangiocyte proliferation and subsequent enlargement
of extrahepatic bile ducts in BA have been linked to over-
expression of IL-33 and activation of TH2 helper T cells. Li
et al110 found that serum levels of IL-33 are elevated in BA
patients and in the livers and bile ducts of experimental
mice. Moreover, treatment of normal wild-type mice with
IL-33 promoted cholangiocyte proliferation and cell growth
that culminated in signiﬁcantly enlarged extrahepatic bile
ducts. They also found that bile ducts genetically primed to
cholangiocarcinoma (by constitutive activation of the pro-
tein kinase B–Yap pathway) responded to administration of
IL-33 via development of advanced tumors with intra-
hepatic metastases compared with controls. Such data sug-
gest that activation of the IL-33 pathway may help biliary
repair and that disruption of the same may halt
carcinogenesis.110
Other studies have implicated the involvement of factors
such as granzymes, which are secreted by hepatic natural
killer and CD8 T cells and injure cholangiocytes in short-
term culture. Consistent with in vitro data, it has been
noted that in infants with BA there is increased hepatic
mRNA expression of granzymes A and B.111 Thus, these
studies offer multiple targets that could be manipulated to
manage cholangiocyte proliferation accompanying liver
conditions such as BA.
The role of microRNA in liver disease also has been
increasingly recognized.112 For example, microRNA-21
(miR-21) was found to be up-regulated during the early
stages of liver regeneration by targeting the Pellino-1 anti-
body.113 The Let-7 family members miR-127, miR-26a, miR-
34a, and miR-23b were all found dysregulated during liver
regeneration. Similarly, during treatment of mice with rhe-
sus rotavirus, microRNA expression proﬁles were found
altered in a time-dependent fashion in the extrahepatic bile
ducts from the experimental animals. For instance, changes
in expression pattern of miR-30b/c, miR-133a/b, miR-195,
miR-200a, miR-365 have been proposed in the develop-
ment of BA.114 Expansion on these reports could provide
alternative treatment protocols for life-threatening condi-
tions such as BA in small children.
Clinical Implications of Recent
Advances in Biliary Research
Despite the enormous progress in recent years, the
pathophysiology of cholangiopathies is far from being
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the development of effective new treatments. Important
signals come from clinical practice. To date, orthotopic liver
transplantation remains the only curative treatment of
cholestatic liver diseases, representing as much as 20% of
the transplantation indications in adults.115 Moreover,
symptoms such as fatigue and pruritus are often scarcely
alleviated by the standard medical approaches.116,117
Ursodeoxycholic acid (UDCA) remains the only approved
drug for the treatment of ﬁbrosing cholangiopathies. UDCA
exerts its effects on multiple levels, from the protection of
cholangiocytes against toxic bile acid to the stimulation of
choleresis through posttranscriptional effects on hepato-
cellular and cholangiocyte transporters.118,119
The administration of UDCA in a daily dose of 13–15 mg/
kg has had well-established, favorable effects on the long-
term survival of PBC patients.120,121 Transplant-free sur-
vival in early-stage PBC patients treated with UDCA has
been shown to be similar to healthy controls matched for
age and gender.122,123 However, not all PBC patients
respond to UDCA administration. A good biochemical
response was achieved only in 61% of PBC patients treated
with UDCA, as deﬁned by the Paris criteria which strongly
correlate with transplant-free survival at 10 years.124
Although the administration of UDCA is universally
recognized as the standard treatment for PBC, deﬁnitive
evidence to recommend its use in PSC is still lacking.
Moreover, the high daily doses of 28–30 mg/kg of UDCA in
PSC patients have been associated with an increased risk of
liver transplantation and development of esophageal vari-
ces.125 In fact, the latest available European guidelines do
not propose any speciﬁc recommendation for UDCA use in
PSC.126
Under these circumstances, the development of alter-
native therapies for cholestatic liver diseases is required,
and intense research is ongoing. Promising results have
recently emerged from the study of two bile acids de-
rivatives: obeticholic acid and norursodeoxycholic acid.
Obeticholic acid (OCA), also known as INT-747, is a
semisynthetic analogue of chenodeoxycholic acid that pos-
sesses a strong farnesoid X receptor (FXR) afﬁnity.127 The
role of FXR in bile acid homeostasis has clearly emerged in
recent years. Endogenous bile acids bind to FXR, which in
turn represses or induces the expression of various genes
involved in their synthesis and secretion, such as cyto-
chrome P450 7A1 (CYP7A1), bile salt export pump (BSEP),
and sodium-taurocholate cotransporting polypeptide 115
(NTCP 115). Chenodeoxycholic acid is the most potent
endogenous FXR ligand (with a 100-fold less afﬁnity than
OCA) whereas UDCA has no afﬁnity. Interestingly, Fxr/
mice have elevated serum bile acid levels, and the infusion
of OCA in rats can stimulate bile ﬂow and protect against
lithocholic acid-induced liver damage.127,128
Given these premises, the efﬁcacy and safety of OCA has
been recently tested in 165 PBC patients who failed to
achieve a good biochemical response to UDCA alone. The
results of the study demonstrated that the administration of
10, 25, or 50 mg of OCA signiﬁcantly reduced levels of
alkaline phosphatase, g-glutamyltransferase, and alanineaminotransferase compared with placebo. However, a sig-
niﬁcant increase in pruritus was also registered; for all three
OCA dosages the severity itching was worse compared with
placebo, but the incidence of pruritus was higher only in the
two higher-dosing groups.129 Phase 2 and phase 3 studies
involving OCA are currently under way, with extremely
promising preliminary results. Indeed, the administration of
5 or 10 mg of OCA has been shown to be superior to placebo
in determining the improvement of biochemical parameters
correlated with clinical outcome in patients with inadequate
response to UDCA.130
Norursodeoxycholic acid (norUDCA) is a C23 homologue
of UDCA with one fewer methylene group in the side chain of
the molecule. The biology of norUDCA has peculiar charac-
teristics; in fact, this bile acid derivative is usually not con-
jugated with taurine or glycine. It is secreted into the bile
canaliculi and reabsorbed by cholangiocytes, and from there
it returns to the liver. The resulting cholehepatic shunting
leads to a bicarbonate rich-choleresis, which is thought to
protect cholangiocytes against the toxicity of bile acids.131,132
Fickert et al84 have tested the possible therapeutic effect of
norUDCA in Mdr2/ mice, a model for sclerosing chol-
angitis. They demonstrated that the administration of nor-
UDCA ameliorated liver tests and liver histology in Mdr2/
mice, in contrast with UDCA which had detrimental effects.85
A recent study of the same group conﬁrmed that norUDCA
improved liver injury in the selective BDL model in mice,
where UDCA administration again was signiﬁcantly more
toxic than norUDCA.133 Based on these results, a phase 2 trial
is currently recruiting patients to test the safety and efﬁcacy
of norUDCA in PSC patients.
Monoclonal antibodies have also attracted the interest of
researches as a possible therapeutic tool to treat chol-
angiopathies. Given the encouraging results obtained with
anti-CD20 antibodies in the dnTGF-bRII mouse model,134
the monoclonal antibody rituximab has been tested in a
phase 1 trial in six PBC patients who have an incomplete
response to UDCA. Rituximab treatment proved to be safe in
PBC patients and transiently reduced serum levels of total
IgG, IgM, and IgA and antimitochondrial antibodies.135
Based on the results of recent genomewide association
studies showing a genetic association between variants of
the IL-2 and IL-23 pathways and PBC,136,137 a phase 2
clinical trial is currently under way to evaluate the safety
and efﬁcacy of ustekinumab, an anti-p40 monoclonal
antibody.
The safety and efﬁcacy of two different monoclonal an-
tibodies (BTT1023 and simtuzumab) are being investigated
in PSC patients. This study is currently in phase 2 clinical
trials. BTT1023 is a human monoclonal antibody targeting
the vascular adhesion protein-1 (VAP-1), a molecule that
has been shown to stimulate the recruitment of effector
lymphocytes to the liver through the up-regulation of the
endothelial cell adhesion molecule MadCAM-1.138,139 Sim-
tuzumab is directed against the lysyl oxidase-like protein 2
(LOXL2), an enzyme that favors the cross-linking of collagen
and elastin ﬁbers.140 The results of these studies will
hopefully lay the basis for possible new and effective
treatments for biliary diseases.
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Our knowledge of the mechanisms regulating biliary cell
responses to injury has grown enormously in the last few
decades.141 Studies from recent years have clariﬁed that
cholangiocytes are not the passive targets of biliary dis-
eases. Indeed, reactive cholangiocytes undergo a series of
profound modiﬁcations and acquire a neuroendocrine-like
phenotype that allows cells to regulate the complex molec-
ular interactions that occur in the diseased liver.4,23 As
discussed in our review, a number of molecular pathways
have been shown to deeply inﬂuence the cholangiocyte
response to injury. Moreover, animal models have proved an
invaluable tool for dissecting the pathophysiologic changes
that occur in the biliary tree in response to injury, providing
important clues on the complex interactions occurring
in vivo. As a result of these continuous efforts, new potential
treatments for PBC and PSC have been developed and are
currently being investigated in clinical trial with promising
results. However, the etiology of many cholangiopathies is
still obscure, and much work remains to be done to trans-
late the large amount of data that have been collected on
disease pathogenesis into effective medical treatments that
can inﬂuence the natural history of biliary diseases.
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